Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report

BACKGROUND: Bevacizumab is an antiangiogenic agent, and that synergizes with chemotherapeutic drugs. When used in combination therapies, Bevacizumab is associated with adverse events such as hemorrhage, gastrointestinal perforation, delayed wound healing, and pneumothorax. However, the molecular mec...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :World J Clin Oncol
Главные авторы: Ozaki, Yuri, Yoshimura, Akiyo, Sawaki, Masataka, Hattori, Masaya, Gondo, Naomi, Kotani, Haruru, Adachi, Yayoi, Kataoka, Ayumi, Sugino, Kayoko, Horisawa, Nanae, Endo, Yuka, Nozawa, Kazuki, Sakamoto, Shoko, Iwata, Hiroji
Формат: Artigo
Язык:Inglês
Опубликовано: Baishideng Publishing Group Inc 2020
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7407928/
https://ncbi.nlm.nih.gov/pubmed/32821655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5306/wjco.v11.i7.504
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы